Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $58 | $55 | $68 | $77 |
| - Cash | $3 | $2 | $3 | $2 |
| + Debt | $3 | $3 | $3 | $3 |
| Enterprise Value | $58 | $56 | $67 | $77 |
| Revenue | $4 | $4 | $3 | $4 |
| % Growth | 2.1% | 21.4% | -20.1% | – |
| Gross Profit | $3 | $3 | $3 | $3 |
| % Margin | 86.1% | 85.6% | 84.7% | 85.1% |
| EBITDA | $2 | $2 | $1 | $1 |
| % Margin | 51.1% | 45.1% | 34.4% | 28.9% |
| Net Income | $1 | $1 | $1 | $1 |
| % Margin | 38.9% | 37.9% | 26.7% | 24.2% |
| EPS Diluted | 13.62 | 12.81 | 7.27 | 8.06 |
| % Growth | 6.3% | 76.2% | -9.8% | – |
| Operating Cash Flow | $2 | $1 | $1 | $1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $1 | $1 | $1 | $1 |